70237-25-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Chloro-2-iodoaniline is used as a key intermediate in the synthesis of indolyl benzoic acid derivatives, which serve as NURR-1 activators. These activators are crucial for the development of treatments targeting Parkinson's disease, a neurodegenerative disorder affecting movement and motor control. By modulating the activity of the NURR-1 receptor, these indolyl benzoic acid derivatives may help alleviate the symptoms and slow the progression of Parkinson's disease.

InChI:InChI=1/C6H5ClIN/c7-4-2-1-3-5(9)6(4)8/h1-3H,9H2

Upstream product

• 603-86-1 2-chloro-6-nitrophenol 
• 32337-97-6 1-chloro-2-iodo-3-nitrobenzene 
• 863870-77-3 3-chloro-2-iodophenyl N,N-dimethyl O-carbamate 
• 1244651-34-0 N-(3-chloro-2-iodophenyl)-2-hydroxy-2-methylpropanamide 
• 1287791-66-5 2-(3-chloro-2-iodophenoxy)-2-methylpropanamide 
• 2845-89-8 1-chloro-3-methoxy-benzene 
• 858854-82-7 3-chloro-2-iodo-phenol 
• 791642-67-6 1-chloro-2-iodo-3-methoxybenzene 
• 159390-33-7 3-chlorophenyl N,N-diethylcarbamate 
• 108-42-9 3-chloro-aniline 
• 121-73-3 3-Nitrochlorobenzene 
• 769-11-9 2-chloro-6-nitroaniline 

Downstream Products

• 72995-15-4 5-chloro-3,4-dihydro-2(1H)-quinolinone 
• 882023-24-7 2-oxo-1,2,3,4-tetrahydroquinoline-5-carbonitrile 
• 1849-73-6 2-mercapto-7-chlorobenzothiazole 

Relevant academic research and scientific papers

Remarkable switch in the regiochemistry of the iodination of anilines by N-iodosuccinimide: Synthesis of 1,2-dichloro-3,4-diiodobenzene

Direct iodination of anilines by NIS in polar solvents (such as DMSO) affords p-iodinated products with up to >99% regioselectivity. Switching to less polar solvents (such as benzene) in the presence of AcOH inverts this outcome toward dramatically increased or preferential generation of the o-isomers, also with up to >99% regioselectivity. This finding was exploited in the synthesis of 1,2-dichloro-3,4-diiodobenzene. Georg Thieme Verlag Stuttgart - New York.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

Approaches to the synthesis of 2,3-dihaloanilines. Useful precursors of 4-functionalized-1 H-indoles

2,3-Dihaloanilines have been proved as useful starting materials for synthesizing 4-halo-1H-indoles. Subsequent or in situ functionalization of the prepared haloindoles allows the access to a wide variety of 2,4- or 2,3,4-regioselectively functionalized indoles in good overall yields. As no efficient synthetic routes to 2,3-dihaloanilines have been described in the literature, different approaches to the preparation of these 1,2,3-functionalized aromatic precursors are now presented. The most general one involves a Smiles rearrangement from the corresponding 2,3-dihalophenols and allows the preparation of 2,3-dihaloanilides in a straightforward and synthetically useful manner.

Efficient total synthesis of (-)-cis-clavicipitic acid

An efficient total synthesis of (-)-cis-clavicipitic acid has been achieved in seven linear steps (42% overall yield) from the known compound 6. The present synthesis features a palladium-catalyzed indole synthesis to provide the optically pure 4-chlorotr

Compounds and Uses Thereof

This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.